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There is currently no approved treatment for primary Sjögren’s syndrome, a disease that
primarily affects adult women. The difficulty in developing effective therapies is -in part-
because of the heterogeneity in the clinical manifestation and pathophysiology of the disease.
Finding common molecular signatures among patient subgroups could improve our under-
standing of disease etiology, and facilitate the development of targeted therapeutics. Here,
we report, in a cross-sectional cohort, a molecular classification scheme for Sjögren’s syn-
drome patients based on the multi-omic profiling of whole blood samples from a European
cohort of over 300 patients, and a similar number of age and gender-matched healthy
volunteers. Using transcriptomic, genomic, epigenetic, cytokine expression and flow cyto-
metry data, combined with clinical parameters, we identify four groups of patients with
distinct patterns of immune dysregulation. The biomarkers we identify can be used by
machine learning classifiers to sort future patients into subgroups, allowing the re-evaluation
of response to treatments in clinical trials.
https://doi.org/10.1038/s41467-021-23472-7 OPEN
1 Institut de Recherches Internationales Servier, Departments of Translational Medicine and Immuno-Inflammatory Diseases Research and Development,
Suresnes, France. 2 LBAI, UMR1227, Univ Brest, Inserm, Brest, France. 3 CHU de Brest, Brest, France. 4Department of Medical Genomics, Center for Genomics
and Oncological Research (GENYO), Granada, Spain. 5 Reina Sofia Hospital, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), University
of Cordoba, Cordoba, Spain. 6Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Catalonia, Spain. 7 Skeletal Biology and
Engineering Research Center, KU Leuven and Division of Rheumatology, UZ Leuven, Belgium. 8 Scleroderma Unit, Referral Center for Systemic Autoimmune
Diseases, Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy. 9 Immunology & Allergy, University Hospital and School of
Medicine, Geneva, Switzerland. 10 University of Szeged, Szeged, Hungary. 11 Klinik für Immunologie und Rheumatologie, Medical University Hannover,
Hannover, Germany. 12 Pharmaceuticals Division, Bayer Pharma Aktiengesellschaft, Berlin, Germany. 13 Università degli studi di Milano, Milan, Italy. 14 Institute
of Parasitology and Biomedicine López-Neyra, Consejo Superior de Investigaciones Científicas (IPBLN-CSIC), Granada, Spain. 29These authors contributed
equally: Perrine Soret and Christelle Le Dantec. *Lists of authors and their affiliations appear at the end of the paper. ✉email: pers@univ-brest.fr









Primary Sjögren’s syndrome (pSS) is a chronic, disabling,complex systemic autoimmune disease that mostly affectsadult women and still lacks a specific therapy. Although the
involvement of salivary and lachrymal glands is the hallmark of
the disease, during pSS progression, various organs and systems
can be involved including joints, lungs, kidneys, liver, nervous
and musculoskeletal system1. Thus, the clinical spectrum of the
disease ranges from a benign slowly progressive autoimmune
exocrinopathy to a severe systemic disorder with significant
symptom heterogeneity and scattered complications. The diag-
nosis of pSS is currently based upon a combination of clinical,
serological, histological, and functional parameters which are
most often only satisfied at a late stage of the disease, i.e., when
glandular dysfunction and symptoms already severely affect a
patient’s overall quality of life. Moreover, one fifth of pSS patients
may present major organ involvement with potentially severe
end-organ damage2 and five percent of patients may also develop
non-Hodgkin’s lymphoma3. Primary SS is one of the few pro-
totypic diseases to link autoimmunity, cancer development and
infections, offering unique insights in many areas of basic science
and clinical medicine. However, the pathogenesis of the disease
remains elusive. Specifically, limited knowledge of existing pSS
disease variants arguably represents the greatest obstacle to
improve patients’ diagnosis and identify patients’ subsets in view
of early stratification and personalized treatment4. It was recently
shown in the PRECISESADS IMI JU project that systemic
autoimmune diseases exhibit a diverse spectrum and a complex
nuanced or overlapping molecular phenotype with four clusters
identified, representing ‘inflammatory’, ‘lymphoid’, ‘interferon’
and ‘healthy-like’ patterns each including all diagnoses and
defined by genetic, clinical, serological and cellular features5.
Many of them share susceptibility genes6 and an overexpression
of interferon (IFN) inducible genes known as the IFN signature is
observed in many of these patients7. Such autoimmune diseases
are driven by numerous environmental factors, therefore dis-
playing a marked variability in their natural course as it relates to
their initiation, propagation and flares.
The present study was undertaken to establish a precise
molecular classification of patients affected by pSS into more
homogeneous clusters whatever their disease phenotypes, activity
or treatment. We report herein on the integrated molecular
profiling of 304 pSS patients compared to 330 matched healthy
volunteers (HV) performed using high-throughput multi-omics
data collected within the PRECISESADS IMI JU project (genetic,
epigenomic, transcriptomic, combined with flow cytometric data,
multiplexed cytokines, as well as classical serology and clinical
data). We identify 4 groups of patients with distinct patterns of
immune dysregulation. The Cluster 1 (C1), C3 and C4 display a
high IFN signature reflecting the pathological involvement of the
IFN pathway, but with various Type I and II IFN gene enrich-
ment. C1 has the strongest IFN signature with both Type I and
Type II gene enrichment when compared to C3 (intermediate)
and C4 (lower). C4 has a Type II gene enrichment stronger than
Type I and equivalent to C3 while C3 has the opposite compo-
sition. C2 exhibits a weak Type I and Type II IFN signature with
no other obvious distinguishable profile relative to HV. We fur-
ther characterized C1, C3 and C4 using multi-omics and clinical
data. C1 patients present a high prevalence of SNPs, C3 patients
an involvement of B cell component more prominent than in the
other clusters and especially an increased frequency of B cells in
the blood while C4 patients have an inflammatory signature
driven by monocytes and neutrophils, together with an aberrant
methylation status. Algorithms derived from machine learning
discriminate the 4 clusters based on distinct biomarkers that can
be easily used in a composite model to stratify patients in clinical
trials. This composite model is validated by using an independent
inception cohort of 37 pSS patients. In conclusion, this work
provides a clear understanding of pSS heterogeneity providing
clinically and immunopathologically relevant signatures to guide
precision medicine strategies. Decision trees coming from this
patient classification have an immediate application to re-evaluate
response to treatments in clinical trials.
Results
Four functional molecular clusters of pSS patients were iden-
tified. Our initial study population comprised 382 pSS patients
enrolled in the PRECISESADS cross-sectional study. Following
complete quality control and diagnosis validation (each patient
had to present either anti-SSA/Ro antibody positivity or focal
lymphocytic sialadenitis with a focus score of ≥1 foci/mm2), 78
patients were removed (Supplementary Fig. 1a–c). Patient char-
acteristics are presented in Table 1. To perform the clustering of
the remaining 304 samples, transcriptomics data were analyzed
with a semi-supervised robust approach previously applied to
breast cancer8 that iterates unsupervised and supervised steps and
relies on the concordance between 3 methods of clustering (see
Methods). Samples were divided into a discovery set and an
independent validation set, representing 75 and 25% of samples,
respectively. The discovery set allowed to cluster patients in four
groups, as confirmed in the validation set (Fig. 1a). When the two
sets were merged, Cluster 1 (C1) contained 101 patients (33.2%),
Cluster 2 (C2) 77 patients (25.3%), Cluster 3 (C3) 88 patients
(28.9%) and Cluster 4 (C4) 38 patients (12.5%). The supervised
step allowed to select a subset of 257 top genes discriminating the
4 clusters of patients (Supplementary Fig. 2) and divided into 3
modules: M.a (105 genes), M.b (20 genes) and M.c (132 genes).
An enrichment analysis was used to annotate each gene module,
showing that M.a was enriched in IFN signaling, M.b in lymphoid
lineage pathways and M.c in inflammatory and myeloid lineage
transcripts (Supplementary Fig. 3). C1, and to a lesser extent C3,
presented overexpression of gene module M.a, whereas
C3 showed overexpression of M.b as well and C4 strong over-
expression of M.c (Fig. 1a). Because C2 had no obvious dis-
cernible pattern, healthy volunteers (HV) were assigned to the 4
molecular clusters distance to centroids (Fig. 1b). When projected
into the patient population, HV did not constitute a separate
cluster but mainly matched with C2 (0.5%, 93%, 4% and 2.5% of
HV merged with C1, C2, C3, and C4, respectively). This means
that the C2 transcriptional signature is not different from HV, at
least at the blood level. Interestingly, our data are consistent with
the previous observation of a healthy-like patient group detected
in a pooled population of 7 different autoimmune diseases5.
We then assessed whether covariates like systemic treatments
could drive the transcriptome-based clustering. Indeed, half of the
pSS patients were treated with either anti-malarials, immuno-
suppressants, or steroids at the time of the visit with a statistically
significant difference in the distribution among the four clusters
(p-values were respectively 0.002 for anti-malarials, <0.001 for
immunosuppressants and steroids) (Table 2). When compared to
the 3 other clusters, a higher proportion of patients treated with
anti-malarials in C2 and a higher proportion of patients receiving
immunosuppressants or steroids in C4 were observed. Impor-
tantly, sensitivity analyses of treated versus untreated patients in
each cluster showed no impact of treatments on cluster
distribution (Supplementary Fig. 4).
In depth functional pathway analysis of individual pSS clusters.
To investigate molecular processes and their biological function
underlying each of the pSS patients’ clusters, specific differentially
expressed genes (DEG) signatures compared to HV were assessed
using Limma in the 4 clusters. Ingenuity Pathway Analysis (IPA)
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was subsequently applied to determine the most significantly
dysregulated canonical pathways with Benjamini–Hochberg false
discovery rate (FDR) adjusted p-value ≤ 0.05 and absolute fold
change (FC) ≥ 1.5. As a result, 284 DEG were found significant in
C1, 301 DEG in C3 and 1686 DEG in C4 (Supplementary Data 1).
Since no DEG were noticed in C2 when compared to HV, only
C1, C3, and C4 were functionally annotated. Top 20 significant
canonical pathways within each DEG signature are presented in
Supplementary Data 2 and pathways related to the most
significantly enriched immunological responses are reported as
radar plots in Fig. 1c. While all 3 clusters were enriched in genes
involved in antiviral and anti-bacterial responses indicative of an
innate-mediated activation profile, C1 was mainly enriched with
IFN-related pathways including IFN signaling, role of pattern
recognition receptors for bacteria and viruses and Interferon
Regulatory Factor (IRF) activation. Notably, C3 and C4 were
further characterized by alterations in biological networks linked
to adaptive immunity. Specifically, significant activation of
canonical pathways related to B cell activation such as B cell
receptor signaling, and B cell development were observed in C3.
In addition, comparative analyses provided evidence for IL7-
signaling up-regulation and LXR/RXR activation in C3
compared to C1.
Interestingly, C4 was the endotype with the highest number of
DEG compared to HV with highly heterogeneous dysregulated
canonical pathways. Ingenuity pathway analysis confirmed the
activation of T and B lymphocyte related pathways reflecting Th1
and Th2 activation, B cell receptor signaling, together with
prominent inflammatory signatures most particularly linked to
cytokine signaling (IL-6 and IL-10 signaling, IL-15 production,
STAT-3 pathway).
Further upstream regulator analysis predicted significant
activation of IFN-α in all three clusters, as well as CpG ODN
in C3 and LPS, IFNγ, TNF-α, and IL-4 in C4, further highlighting
B cell activity and inflammatory responses in C3 and C4,
respectively.
Noteworthy, while C2 displayed no DEG compared to HV, 14
genes were differentially expressed in C2 patients positive for SSA
antibodies compared to HV whereas only 2 DEG were found in
SSA-negative C2 patients. These SSA-positive C2 patients were
characterized by significant enrichment in IFN-related genes
compared to HV including IFI44, IFI44L, IFI6, IFIFT1, IFIT3,
ISG15, MX1, OAS3, SERPING1, and SIGLEC1 (Supplementary
data 1).
To further characterize patient cluster variability at a molecular
level, we then used the blood transcriptome modular repertoire
recently established on an expended range of disease and
pathological states. The latter includes 382 transcriptome
modules based on genes co-expression patterns across 16 diseases
and 985 unique transcriptome profiles9. Again, no aggregate was
found differentially expressed in C2 confirming the healthy-like
profile of these patients, whereas an up-regulated IFN signature
dominated in C1, C3, and C4 (Fig. 2). In C4, the most induced
modules include genes associated with inflammation and
neutrophils. As the highest inflammatory phenotype, C4 is
associated with a hypercytokinemia/hyperchemokinemia
Table 1 Healthy volunteers (HV) and Primary Sjögren’s syndrome (pSS) patient characteristics.







Age n 330 227 77 304
Mean ± SD 53.294 ±
10.998
58.524 ± 13.440 58.039 ± 13.554 58.401 ± 13.448
Gender n 330 227 77 304
Female n (%) 302 (91.52) 211 (92.95) 71 (92.21) 282 (92.76)
Obesity (BMI >= 30) n 328 218 74 292
Yes n (%) 24 (7.27) 30 (13.76) 3 (4.05) 33 (11.30)
Race n 330 227 77 304
Asian n (%) 2 (0.61) 1 (0.44) 1 (1.30) 2 (0.66)
Black/African
American
n (%) — — 1 (1.30) 1 (0.33)
Caucasian/White n (%) 328 (99.39) 224 (98.68) 74 (96.10) 298 (98.03)
Other n (%) — 2 (0.88) 1 (1.30) 3 (0.99)
Diagnostic criteria
Focus score > 1 n — 82 27 109
Yes n (%) — 73 (89.02) 24 (88.89) 97 (88.99)
Anti-SSA positivity n — 227 77 304




n — 225 77 302
Mean ± SD — 10.788 ± 7.535 11.094 ± 9.620 10.866 ± 8.101
Disease activity
(PGA*)
n — 211 75 286
Mean ± SD — 25.687 ± 18.976 24.840 ± 20.984 25.465 ± 19.488
ESSDAI (**) n — 133 60 193
Mean ± SD — 4.609 ± 5.358 4.850 ± 5.495 4.684 ± 5.388
ESSPRI (**) n — 106 44 150
Mean ± SD — 5.176 ± 2.286 4.568 ± 2.648 4.998 ± 2.405
n: Number of patients with available information.
(*) PGA: Physician Global Assessment.
(**) collected in a substudy.
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observed in modules (M13.16, M15.84, M16.80) consistent with
an upregulation of the TNF-associated module (M16.47) and a
downregulation of the TGFβ-associated module (M16.65) (Fig. 2).
Some modules were under-expressed, such as those associated
with both protein synthesis (M12.7, M11.1, M13.28, M14.80), B
cells (M13.27, M12.8) and T cells (M15.38, M14.42, M12.6).
Genes mainly overexpressed in C1 were also implicated in
inflammatory responses and neutrophils (A33, A35), in parallel
with down-regulated B and T cell signatures (Supplementary
Fig. 5). Moreover, distinct sub-modules expressed in opposite















Role of JAK1, JAK2 and TYK2 in Interferon Signaling
Communication between Innate and Adaptative Immune Cells
Antigen Presentation Pathway
Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza
Fig. 1 Molecular pattern distribution is represented by 4 clusters of pSS patients with different canonical pathways. a Heatmap performed for 304 pSS
patients (Discovery set: 227, Validation set: 77) showing the distribution of gene transcripts across the 4 clusters. In columns patients are grouped by
cluster assignment and in rows genes are grouped by functional modules. Each subset of patients (discovery set on the left and validation set on the right)
is presented separately. Red represents overexpression and blue represents under-expression. At the top of the figure annotations show: each of the
treatment groups for each individual (AM: antimalarials, STED: steroids and IMS: immunosuppressors, red represents patients with treatment and gray
represents patients without treatment), age (levels of yellow to green with yellow for younger patients and dark green for older patients), gender (red
represents woman and gray represents man), ANTISSAPOS: anti-SSA/Ro antibody positivity, FOCUSSCOREPOS: focus score of ≥1 foci/mm2 (red
represents focus score of ≥1 foci/mm2 and gray represents focus score of <1 foci/mm2). b Scatterplot of the first two components PCA (performed for 304
pSS patient and 330 HV) model showing clearly defined clusters in signature gene. HV (gray dot) are confused with C2 cluster (yellow dot). c Top 20 most
significant canonical pathways for each cluster. Radar plots are represented according to ‒log (p-value) (Fisher’s exact test) associated to the most
significant pathways of each cluster; C1 (pink), C3 (green), C4 (blue).
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directions allows to functionally discriminate C1 and C3. Patients
from C3 demonstrated a significant under-expression of modules
related to erythrocytes (A37; M9.2, M11.3) and cytokines/
chemokines (A35; M15.84, M13.16) and an increased expression
in some of the B cell modules (A1; M12.8) (Supplementary Fig. 5
and Fig. 2).
IFN signatures. Consistent with the literature, the most sig-
nificantly enriched pathway confirmed to be up-regulated in all
three clusters was the IFN signaling pathway (Fig. 2, Supple-
mentary Fig. 5). In SLE, Chiche et al. have previously identified
three strongly up-regulated IFN-annotated modules (M1.2, M3.4,
and M5.12) from peripheral blood transcriptomic data, with for
each module a distinct activation threshold10. Genes within the
M1.2 module are induced by IFNα, while other genes from both
M1.2 and M3.4 are up-regulated by IFNβ, corresponding to a
type I IFN signature. The M5.12 genes are poorly induced by
IFNα and IFNβ alone but are rather up-regulated by IFNγ
characterizing a type II IFN signature11. Moreover, transcripts
belonging to M3.4 and M5.12 were only fully induced by a
combination of Type I and Type II IFNs. Kirou et al. made
similar observations and identified genes preferentially induced
by IFNα or IFNγ12. The different z-scores were then calculated
accordingly to characterize further the IFN signature observed in
the various clusters (Fig. 3). All IFN z-scores were increased to
some extent in C2 when compared to HV. In line with the strong
signal observed, C1 patients had the highest Type I and type II
scores. Interestingly, C3 had higher Type I IFN score than C4 but
these 2 clusters were not different for Type II IFN score.
Table 2 Descriptive analysis of the clinical parameters by primary Sjögren’s syndrome cluster.
C1 (n= 101) C2 (n= 77) C3 (n= 88) C4 (n= 38) p-value
Age, years n 101 77 88 38
Mean ± SD 57.327 ± 13.705 58.805 ± 13.688 57.250 ± 12.032 63.105 ± 14.790 0.10
Gender n 101 77 88 38
Female n (%) 96 (95.05) 71 (92.21) 81 (92.05) 34 (89.47) 0.70
Age at onset, years n 101 76 88 37
Mean ± SD 45.663 ± 14.475 50.428 ± 14.532 47.606 ± 12.687 51.739 ± 16.053 0.071
Disease duration, years n 101 76 88 37
Mean ± SD 12.247 ± 8.921 8.965 ± 7.336 10.183 ± 7.210 12.625 ± 8.524 0.029
Disease activity (PGA*) n 94 71 85 36
Mean ± SD 27.245 ± 20.535 22.718 ± 17.698 23.212 ± 18.766 31.556 ± 20.646 0.092
ESSDAI n 70 52 44 27
Mean ± SD 5.029 ± 5.959 3.731 ± 4.594 4.227 ± 4.017 6.370 ± 6.828 0.10
ESSPRI n 56 43 30 21
Mean ± SD 4.833 ± 2.460 5.031 ± 2.429 5.300 ± 2.703 4.937 ± 1.803 0.87
Arthritis n 98 77 86 38
Past n (%) 39 (39.80) 18 (23.38) 20 (23.26) 12 (31.58) 0.016
Present n (%) 2 (2.04) 3 (3.90) 4 (4.65) 5 (13.16)
Focus score > 1 n 96 29 21 14
Yes n (%) 39 (40.63) 28 (96.55) 17 (80.95) 12 (85.71) 0.4
Anti-SSA positivity n 101 77 88 38
Yes n (%) 99 (99.00) 56 (72.72) 87 (98.86) 31 (81.57) <0.001
Anti-SSB positivity n 100 77 86 38
Yes n (%) 61 (61.00) 12 (15.58) 39 (45.35) 11 (28.95) <0.001
Hypergammabulinemia n 97 73 86 38
Past n (%) 23 (23.71) 8 (10.96) 9 (10.47) 3 (7.89) <0.001
Present n (%) 44 (45.36) 10 (13.70) 41 (47.67) 7 (18.42)
Abnormal inflammatory indexes n 100 77 87 38
Past n (%) 28 (28.00) 13 (16.88) 20 (22.99) 12 (31.58) 0.003
Present n (%) 35 (35.00) 11 (14.29) 22 (25.29) 10 (26.32)
Reduced C3 levels n 93 74 82 35
Past n (%) 13 (13.98) 5 (6.76) 11 (13.41) 4 (11.43) 0.8
Present n (%) 7 (7.53) 4 (5.41) 5 (6.10) 3 (8.57)
Reduced C4 levels n 93 74 82 35
Past n (%) 13 (13.98) 3 (4.05) 9 (10.98) 4 (11.43) 0.10
Present n (%) 10 (10.75) 3 (4.05) 3 (3.66) 4 (11.43)
Abnormal Creatinine n 98 77 88 38
Past n (%) 10 (10.20) 4 (5.19) - 2 (5.26) 0.009
Present n (%) 5 (5.10) 2 (2.60) 7 (7.95) 6 (15.79)
Proteinuria n 65 58 56 25
Moderate n (%) 5 (7.69) 2 (3.45) 1 (1.79) 3 (12.00) 0.093
Past n (%) 5 (7.69) — 3 (5.36) —
Current use of antimalarials n 101 77 88 38
Yes n (%) 33 (32.67) 42 (54.55) 24 (27.27) 15 (39.47) 0.002
Current use of Immunosuppressants n 101 77 88 38
Yes n (%) 17 (16.83) 14 (18.18) 7 (7.95) 15 (39.47) <0.001
Current use of steroids n 101 77 88 38
Yes n (%) 23 (22.77) 14 (18.18) 10 (11.36) 23 (60.53) <0.001
n: Number of patients with available information, (*) PGA: Physician Global Assessment.
Statistical tests performed: chi-square test of independence for categorial variable and Kruskal–Wallis test for continue variable.
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Upstream analysis of C4 DEG predicted IFNγ as an important
regulator suggesting that Type II IFN activation was prominent
in C4.
Genome-wide association study analysis. We investigated whe-
ther clusters showed any differences in the genetic contribution of
risk alleles known to be associated with pSS13–15. Even in the
mid-size cohort of patients analyzed (304 pSS and 330 HV), we
unambiguously detected (with signals genome wide significance
level <5 × 10−8) 35 single nucleotide polymorphisms (SNPs) in
C1 compared to only six in C3 and one in C4 (Fig. 4a, Supple-
mentary Data 3). Interestingly, no significant enrichment was
found in C2. The 35 SNPs assessed in C1 are found within genes
associated with either the immune system (HLA-DQB1, HLA-
DQA1, HLA-DRA, HLA-C, HLA-G), signal transduction
(NOTCH4), developmental biology (POU5F1), gene expression
(DDX39B) or cell cycle (TUBB). The presence of such significant
genetic associations was already found in clusters of systemic
autoimmune disease patients whose molecular disease pathway is
the Type I IFN pathway5. Moreover, a strong association of SNPs
with HLA class II genes was reported in SLE patients with a high
level of autoantibodies16. One SNP (rs2734583) was common to
C1 and C3 and is associated to the DDX39 gene. Of note,
DDX39B, the protein encoded by this gene, is required for the
prevention of dsRNA formation during influenza A virus infec-
tion, thereby preventing the activation of the Type I IFN
system17. The five others SNPs in C3 are nearby HLA-DQA,
HLA-DRA (2 SNPs), BTNL2 and HCG23. The only SNP
(rs2247056) found in C4, also common with C1, is located in
intron 1 of the LINC02571 gene and was previously associated
with a risk for developing SLE.
Linkage disequilibrium is a non-random association of alleles
at different loci in a given population. When analyzing linkage
disequilibrium (Fig. 4b) in the loci of the 35 SNPs detected in C1
and located on chromosome 6 (from base 29809362 to
32681631), three SNPs were strongly associated in HLA-DQA1
locus (rs9272219, rs9271588, rs642093), five SNPs in HLA-DRA |
HLA-DQA1 locus (rs7195, rs1041885, rs3129890, rs9269043,
rs7749057) and three SNPs in HCG27 |HLA-C locus (rs3130473,
rs2394895 and rs3130467). Two other regions contain strongly
associated SNPs. The NOTCH4 | C6orf10 locus presented 5
associated SNPs (rs3130347, rs204991, rs3132935, rs7751896,
rs9268220) as well as the IER3 |DDR1 locus (rs3094122,
rs6911628, rs3094112, rs2517576, rs3095151).
Methylation analysis. The methylation analysis was performed
with a Benjamini Hochberg FDR < 0.1 and absolute ΔBeta >
0.075. Only two differentially methylated positions (DMPs) cor-
responding to two genes were found in C2. Those DMPs were
common with the 3 other clusters (Fig. 5a) and were located in
the TSS1500 shore of the NLRC5 gene and in the 5’UTR of the
gene encoding MX1, two genes involved in the IFN signature.
NLRC5 plays a role in cytokine response and antiviral immunity
through inhibition of NF-kappa-B activation and negative reg-
ulation of Type I IFN signaling pathways18. MX1 encodes an IFN
induced dynamic-like GTPase with antiviral activity which was
proposed as a clinically applicable biomarker for identifying
systemic Type I IFN in pSS19.
145 DMPs corresponding to 87 genes and 96 DMPs
corresponding to 56 genes were found in C1 and C3 respectively,
whereas an aberrant methylation status with 8,445 DMPs
corresponding to 3,636 genes characterized C4 (Fig. 5a). In order
to test whether the methylation defect in C4 was associated with
steroids treatment, we compared the 9 untreated to the 17 treated
patients. No CpG with a Benjamini-Hochberg FDR adjusted p-
value < 0.1 was found to be differentially methylated in treated
versus untreated patients. A global hypomethylation of CpG was
observed for all clusters (89.6% in C1, 100% in C2, 67.7% in C3
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Fig. 2 Patterns of abundance of the different modules distinguish the four pSS clusters. Each heatmap, achieved with BloodGen3Module R package9,
represents one of the most significant patterns differentiating the four clusters of 304 pSS patients (C1: 101, C2: 77, C3: 88, and C4: 38) compared to 330
healthy volunteers (HV). These patterns correspond to modules associated with IFN, neutrophils, inflammation, cytokines/chemokines, protein synthesis,
erythrocytes, monocytes, B cells and T cells. Columns on this heatmap corresponds to clusters. Each row corresponds to one of the modules associated
with the pattern. For each module, the percentage of increased genes (from 0 to 100) and decreased genes (from 0 to 100) were calculated. A red spot on
the heatmap indicates an increase in abundance of transcripts comprising a given module for a given cluster. A blue spot indicates a decrease in abundance
of transcripts. The absence of color indicates no changes.
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Fig. 3 The 4 pSS clusters show typical IFN signature according to modular IFN z-scores. IFN score analyses were performed for 304 pSS patients and
330 healthy volunteers (HV). Repartition of samples from the 4 pSS clusters are shown according to the most characterized IFN module z-scores. The
genes (IFI44, IFI44L, IFIT1 and MX1) of the M1.2 module (a) are induced by IFNα, while genes from both M1.2 and M3.4 (b) (ZBP1, IFIH1, EIF2AK2, PARP9
and GBP4) are up-regulated by IFNβ. c The genes (PSMB9, NCOA7, TAP1, ISG20 and SP140) from the M5.12 module are poorly induced by IFNα and IFNβ
alone while they are up-regulated by IFNγ. Moreover, transcripts belonging to M3.4 and M5.12 were only fully induced by a combination of Type I and Type
II IFNs10. Other modules identified genes preferentially induced by IFNα (IFIT1, IFI44 and EIF2AK2) (d) or IFNγ (IRF1, GBP1 and SERPING1) (e)12. Two-tailed




































































































































































































































































Fig. 4 Cluster genome-wide association analyses (GWAS). GWAS analysis was performed using Plink, an open-source whole genome association
analysis toolset, using a logistical regression for 304 pSS (C1: 101, C2: 77, C3: 88 and C4: 38) patients and 330 healthy volunteers (HV) and each cluster
was compared to HV. a Manhattan plots for each cluster are shown. b Linkage disequilibrium analysis in the loci of the 35 SNPs detected in C1 and located
on chromosome 6 from base 29809362 to base 32681631. The R2 correlation coefficient and linkage disequilibrium heatmap were obtained with Plink, and
oncofunco R package, respectively. Strongest associations between SNPs are annotated.
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and 80.4% in C4). Because functionally important DNA
methylation occurs in promoter regions and in CpG islands20,
DMP distribution across the different genomic regions was
investigated (Fig. 5b). A higher representation of DMPs in the
promoter region was found in C3 (36.4%) and C1 (33.1%) when
compared to C4 (29.1%). The consequence was a lower
representation of DMPs in intergenic regions for C3 (8.8%)
compared to C1 (22.8%) and C4 (23.1%). To gain insight on this
pattern, we divided the probes according to CpG islands; shores
(regions up to 2 kb from CpG island), shelves (regions from 2 to
4 kb from CpG island) and open sea (the rest of the genome).
Interestingly, 21.8% of the DMPs for C3 were located in CpG
islands versus 6.9 and 7.4% for C1 and C4, respectively.
To identify the most robust and significant signature of hypo-
and hyper-methylated genes, we fixed the ΔBeta cut-off at 0.15.
Regarding hypomethylated CpGs, 13 DMPs were found in C1, 17
in C3 and 1,194 in C4, corresponding to 10, 11 and 761
hypomethylated genes, respectively. Five genes with hypomethy-
lated DMPs were common to these 3 clusters (IFI44L, IFIT1,
MX1, PARP9 and PLSCR1) (Fig. 5c), corresponding to genes
reported to present strong interactions (Fig. 5d). Interestingly,
these genes were also significantly hypomethylated in C2 when
compared to HV (Supplementary Fig. 6). Of note, 5 additional
genes (HLA-A, DDX60, CMPK2, IFITM1 and NLRC5) were
common to C1 and C3 and were also strongly associated with the
previous ones, reinforcing the IFN signature in these two clusters
(Fig. 5e). These common 10 hypomethylated genes are implicated
in defense responses to virus and are induced by IFN21.
The remaining 756 hypomethylated genes in C4 were mainly
associated with the neutrophil degranulation pathway. Regarding
hypermethylated CpGs, 41 DMPs corresponding to 25 genes were
only found in C4. Those genes are mainly implicated in
translocation of ZAP-70 to the immunological synapse, phos-
phorylation of CD3 chains including zeta, platelet activation,
signaling and aggregation, homeostasis and PD-1 signaling.
Combining transcriptomic (FC ≥ 1.5) and methylomic (abso-
lute ΔBeta > 0.15) analyses, the transcripts of 8, 8 and 126 genes
were found to be increased in association with a decreased
methylation status in C1, C3 and C4, respectively. Interestingly,
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Fig. 5 Methylation analysis confirms the strong IFN signature in C1 and C3 and reveals an aberrant methylation status in C4.Whole blood methylation
analysis was performed for 226 pSS patients (C1: 81, C2: 57, C3: 62, and C4: 26) and 175 healthy volunteers (HV) doing pairwise comparisons between
each cluster and HV. a Venn diagram showing the overlap of differentially methylated CpG sites and genes between the 4 clusters with absolute ΔBeta >
0.075. b DMP distribution across the different genomic regions (gene body, 3’UTR, intergenic (IGR), 5’UTR, Exon 1, TSS 1500 and TSS 200; and according
to the CpG density to CpG island, shelf, shore, and open sea. c Venn diagram showing the overlap of hypomethylated CpG and genes with absolute ΔBeta
> 0.15 between the three IFN clusters. d Interaction network of these 5 genes common to the three clusters by STRING analysis with a confidence cut-off of
0.4 reveals a common IFN signature. e Interaction network of the 10 genes hypomethylated common to C1 and C3 by STRING analysis with a confidence
cut-off of 0.4. f Reactome analysis22 of the functional pathways enriched for the 126 genes hypomethylated and over expressed in C4 (absolute ΔBeta >
0.15, FC≥ 1.5).
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implicated in IFN signaling were also overexpressed at the
transcriptional levels in the 3 clusters. Transcript overexpression
was strongly associated with hypomethylation in C1 (8/10) and
C3 (8/11) and to a less extend in C4 (126/761). Among the 126
genes from C4, 21 were implicated in neutrophil degranulation
which constitutes the most relevant pathways according to
Reactome Pathway Database22 (Fig. 5f). Only 6/25 transcripts
were repressed in association with an increased methylation
status of their genes in this cluster (CD247, CD3G, CDC25B,
CXCR6, TBC1D4, UBASH3A).
Flow cytometry analysis. As significant alterations in patterns of
peripheral blood leukocytes have been previously described23,24,
we then investigated the composition of leukocyte subsets in the
various clusters. (Fig. 6a, b, Supplementary Fig. 7). In C2, the
frequency and absolute numbers were similar to HV in all the
different subsets analyzed. An increase in the frequency of
monocytes and lymphocytes characterized C3, in association with
a marked increase in the frequency of B cells. At the same time, a
lymphopenia affecting mainly T cells was found in C1. Finally,
the most distinguishable cluster in terms of distribution and
absolute number of cells is C4. Specifically, C4 was characterized
by higher percentages and absolute numbers of PMN (especially
neutrophils) in peripheral blood in comparison with those in
other clusters and HV. Conversely, the percentages of lympho-
cytes (B and T cells) and monocytes were markedly decreased in
C4 compared to either the controls or the other clusters. Finally,
lower frequencies and absolute numbers of basophils and DCs
were also found in this cluster.
An in-depth analysis of the different cell subpopulations was then
conducted. First, monocytes represent a heterogeneous cell
population in terms of both phenotype and function. Based on
the expression of CD14 and CD16, 3 monocyte subsets can
be defined, including classical (CD14++CD16–), intermediate
(CD14++CD16+) and non-classical (CD14+CD16++). Classical
monocytes are critical for the initial inflammatory response, can
differentiate into macrophages in tissue and contribute to chronic
disease. Intermediate monocytes are highly phagocytic cells that
produce high levels of ROS and inflammatory mediators. Non
classical monocytes have been widely viewed as anti-inflammatory,
as they maintain vascular homeostasis and constitute a first line of
defense in recognition and clearance of pathogens25. Interestingly,
the frequency and absolute number of intermediate monocytes were
increased in C1 and C3 whereas the frequency of classical
monocytes was decreased when compared to the 2 others and the
nonclassical subset was markedly decreased in C4, in line with the
inflammatory response observed in these different clusters.
Second, NK cells are defined by the expression of CD56 and
the lack of CD3-TCR complex. Moreover, based on CD16 and
CD56 expression levels, they are classified in two subsets:
CD56hiCD16lo and CD56loCD16hi. The latter NK cell subset
mediates natural and antibody-dependent cellular cytotoxicity,
exhibiting high levels of perforin and enhanced killing. In
contrast, CD56hiCD16lo NK cells are characterized by low levels
of perforin, and are primarily specialized for cytokine production
including IFN26,27. Accordingly, the frequency of CD56hiCD16lo
NK cells subset over CD56loCD16hi was increased in C4, C1, C3
and to a lower extent in C2. This may partly explain the up-
regulation of cytokines and interferon pathways in disease
clusters. Although plasmacytoid dendritic cells (pDCs) are
thought to represent the main IFNα producing cells, no
differences were observed between clusters and their reduction
was confirmed in peripheral blood of pSS patients when
compared to HV28.
b c
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Fig. 6 Cell subset distribution in blood and cytokines, chemokines and inflammatory mediators in serum in the 4 clusters and healthy volunteers (HV).
a Flow cytometry analysis was performed for 283 patients (C1: 96, C2: 71, C3: 80, and C4: 36) and 309 HV. The 2 heatmaps show the mean distribution of
blood cell subsets in frequency (0–100%) and in absolute numbers (per µL of blood) across the 4 clusters and HV assessed by flow cytometry. Columns
represent clusters and HV and rows the different cell subsets. The asterisk means that the cluster (or HV) is statistically different from all the others.
b Flow cytometry data represented by bar charts cell types proportion per cluster. c Serum mediators were analyzed for 192 pSS patients (C1: 67, C2:48,
C3: 61, C4:16) and 171 HV. Patient and HV distribution according to each analyzed variable is described in Methods. CXCL13/BLC, FAS Ligand, GDF-15,
CXCL10/IP-10, CCL8/MCP-2, CCL13/MCP-4, CCL4/MIP-1β, MMP-8, CCL17/TARC, IL-1 RII, TNF-RI, and IL1-RA were measured using the Luminex system
and expressed as pg/ml. Soluble MMP-2, CRP, TNFα, IL-6, BAFF, and TGFβ were measured by the quantitative sandwich enzyme immunoassay technique
and expressed as pg/ml. Cytokine or chemokine concentration levels for each cluster were compared to HV. Statistical significance is determined using a
one-way ANOVA followed by post-hoc Tukey’s test. The significance between the cluster and HV is represented as bullet ranging from small (non-
significant) to big (significant). The direction of the association is shown as the z-score where red bullet is up-regulated, and blue bullet is down-regulated.
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Cytokine analysis. We subsequently assessed whether pSS clus-
ters also showed differences in systemic parameters of inflam-
mation, such as cytokines, chemokines and other soluble factors
(Fig. 6c and Supplementary Fig. 8). The IFNγ-induced protein
(CXCL10/IP-10) as well as CCL8/MCP-2 and TNFα were
increased in C1 and C3, i.e. the two main clusters associated with
a strong IFN signature. At the same time, IL-1 RII, the decoy
receptor for cytokine belonging to the IL-1 family, was down
regulated in C1 and C3. Overall, C1 was largely enriched in
CXCL13/BLC, IL-6, and IL-1RA. Levels of MMP-8, a protease
mainly expressed by neutrophils, were not different from HV in
C4 but lower in the other clusters. Of note, many cytokines such
as CXCL10/IP-10, CXCL13/BLC, BAFF, and GDF15 were
increased in all clusters including C2 when compared to HV.
However, no differences between clusters were found for CRP,
Fas Ligand, CCL13/MCP-4, CCL4/MIP-1β, CCL17/TARC and
TGFβ.
To confirm that patients with an active IFN signature have
elevated circulating Type I IFN, we measured levels of IFNα in
plasma using Simoa Single Molecule Array Technology in pSS
patients and HV. Median levels of IFNα in plasma were 807
(177–1744) fg/ml and 530 (106–1033) fg/ml in C1 and C3,
respectively, while circulating levels in the other clusters and
HV were close to the lower limit of quantification (Supplementary
Fig. 9a). Interestingly, IFNα in serum was positively correlated
with the two IFN transcriptomic modules (M1.2 and IFNα
module) described in Fig. 3, especially in C1 and to a lesser extent
in C3, confirming the Type I IFN signature observed in these
patients (Supplementary Fig. 9b). Of note, half of the patients in
C2 received antimalarials and previous studies have also shown
that hydroxychloroquine use can reduce the levels of circulating
Type I29,30 and Type II31,32; IFN z-scores. IFNα in serum was not
associated with ESSDAI (Supplementary Fig. 9b) but higher levels
of serum IFNα were associated with hematological and biological
domains of ESSDAI (Supplementary Data 4).
Clinical symptoms and serological characteristics. Patient
medical history and disease characteristics including clinical and
serological parameters were collected for the 304 pSS patients.
Details are displayed in Table 2 and Supplementary Data 5.
Patients from C2 had a lower disease duration when compared to
patients from other clusters.
Although the Physician Global Assessment (PGA) was
collected for the whole population, ESSDAI and ESSPRI were
only assessed in expert centers (Barcelona, Brest, Cordoba,
Geneva, Hannover, Leuven, Milano, Porto and Szeged) in a subset
of 193 and 150 respectively of the 304 pSS studied patients (70/
101 and 56/101 from C1, 52/77 and 43/77 from C2, 44/88 and 30/
88 from C3 and 27/38 and 21/38 from C4, Supplementary
Data 5).
The lowest mean ESSDAI score was observed in C2 and the
highest ESSDAI and PGA mean scores in C4 (Table 2, Fig. 7a)
but there were no statistically significant differences between the 4
clusters. No clear difference in the ESSDAI components nor in
the objective measures of ocular and salivary dryness was
observed between the 4 clusters. Moreover, there was no
significant difference for the global ESSPRI score and its 3
components (i.e. dryness, pain and fatigue) except between SSA-
positive C2 patients who reported lower ESSPRI scores (p-value <
0.001) compared to the SSA-negative patients (Supplementary
Data 6).
Statistically significant differences in the distribution of
reported arthritis (p-value= 0.016), rate of cancer history (p-
value= 0.028), coronary artery disease (p-value= 0.002) and
chronic obstructive pulmonary disease (p-value = 0.016) were
observed between the four clusters. (Supplementary Data 7).
Interestingly, patients from C4 reported more severe clinical
symptoms compared to the 3 other clusters.
Some serological characteristics were significantly different
across the 4 clusters, hypergammaglobulinemia (p-value < 0.001)
(Table 2), extractable nuclear antigen (ENA) antibodies (p-value
<0.001), the presence of serum anti-SSA52/anti-SSA60 autoanti-
bodies (p-value < 0.001) and higher circulating kappa and lambda
free light chains (cFLC) (p-value < 0.001) (Fig. 7b, and
Supplementary Data 8). C1 and C3 were associated with higher
levels of these parameters when compared to C2 and C4.
Moreover, C2 and C4 were enriched in patients with glandular
manifestations of the disease assessed by a positive focus score in
the absence of anti-SSA antibodies (Table 2).
In addition, the levels of rheumatoid factor (p-value < 0.001)
and complement C4 fraction levels (p-value= 0.003) were
statistically different between the four clusters. C1 was character-
ized by a higher rheumatoid factor and by a reduced complement
C4 fraction levels compared to the other clusters. While some
patients presented anti-dsDNA antibodies in C1 and C3 and anti-
CCP antibodies in C4, almost none of these autoantibodies were
present in the other clusters (Supplementary Data 8).
Prediction of patient membership to each of the four clusters.
We then developed through machine learning approaches a
composite model able to predict, according to a small number of
variables, to which of the 4 clusters each patient belongs (see
Methods). The proposed composite model was built with a 2-step
approach to allocate patient to the right cluster (Supplementary
Fig. 10). The final sets of selected features were composed of 10
genes for the C4 prediction model (first step) and 31 genes for the
C1, C2, and C3 classification model (second step). The distribu-
tion among clusters of the variance stabilizing transformation
(vst) normalized expression for all these transcripts is shown in
Supplementary Fig. 11. The validation set (Fig. 1 and Table 1) was
used for training, due to the heterogeneity of C4 pSS patients in
this set, and the composite model was then run on the discovery
set. The accuracy of the model was 95.15%, with 99.12% and
95.57%, for the first and the second steps respectively. The con-
fusion matrix, the corresponding discriminant function analysis,
and the probabilities to belong to one of the 4 clusters are shown
in Fig. 8a, b, and Supplementary Data 9, respectively.
To generalize the composite model, we used an independent
inception cohort of 37 pSS patients. After prediction, C1
contained 16 patients (43.2%), C2 6 patients (16.2%), C3 7
patients (18.9%) and C4 8 patients (21.6%). The corresponding
discriminant function analysis and the probabilities for a patient
to belong to one of the 4 clusters are shown in Fig. 8c and
Supplementary Data 10, respectively. We then used the minimal
list of 257 discriminative genes signature previously selected in
Fig. 1a to generate a heat map with the prediction established by
the composite model (Supplementary Fig. 12a). The clusters
observed had the same profile than those identified in the
discovery set and observed again in the validation set (Fig. 1a),
confirming once more the clustering model. Furthermore, the
predicted patients showed a distribution of the IFN signatures
(Supplementary Fig. 12b) consistent with the one characterizing
the identified clusters (Fig. 3). Altogether, these observations
strengthen the validation of our composite model.
Finally, in order to allow our model to process other cohorts of
patients, we implement an interpolation function based on 6
genes presenting a constant expression across all 4 clusters and
HV (Supplementary Fig. 13). The composite model is integrated
into an analysis tool available on the laboratory’s github
repository33.
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Discussion
Over the last decade, numerous targeted immunomodulatory
therapies for pSS have failed to show a benefit in clinical trials,
hence no disease-modifying therapy has yet been approved for
this disease34–39. The heterogeneous nature of pSS and its non-
linear development, with flares of activity and subsequent
remission associated to a very heterogeneous clinical presentation
may explain clinical trial failures40. In this context, there is
growing interest in the identification of well-characterized sub-
groups of patients, a prerequisite to the identification of mole-
cular biomarkers predictive of treatment response41.
We report herein on a large molecular profiling study carried
out in pSS patients, a comprehensive molecular profiling of these
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Fig. 7 Disease activity and serological distributions in the 4 clusters. a ESSDAI collected for 193 pSS patients (C1: 70, C2: 52, C3: 44, C4: 27), PGA
collected for 286 pSS patients (C1: 94, C2: 71, C3: 85, C4: 36,) and ESSPRI collected for 150 pSS patients (C1: 56, C2: 43, C3: 30, C4: 21) distributions are
shown in the 4 clusters. Two-tailed pairwise Wilcoxon-rank sum test results are shown. b The barplot shows the proportion of past (light orange) or
present (orange) hypergammaglobulinemia (C1: 97, C2: 73, C3: 86, C4: 38) in each cluster. c Extractable nuclear antigen antibodies, anti-SSA antibodies,
anti-SSA antibodies (Ro-52), anti-SSA antibodies (Ro-60), anti-SSB antibodies, rheumatoid factor were performed for 304 pSS patients (C1: 101, C2:77,
C3:88, C4:38) and 330 HV and measured in serum, at the same center, using an automated chemiluminescent immunoanalyzer (IDS-iSYS). Barplots show
the proportion of concentration level in each cluster (black: negative, light pink: low, orange: medium, red: elevated and dark red: high). Turbidimetry was
used for rheumatoid factor (RF), complement fractions C3c and C4 determination and circulating free light chains. Statistical significance is determined by
two-tailed pairwise Wilcoxon-rank sum test. Plots show median with error bars indicating ± interquartile range. Patient and HV distribution according to
PGA and biological parameters analyzed variable is described in Methods.
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in pSS focus particularly on the IFN signaling involvement11.
Thereby, pSS patients could be stratified in interferon negative,
Type I or Type I+ II positive subgroups with higher prevalence
of anti-SSA and anti-SSB among those with IFN activation
without relation with systemic activity. Another group42 per-
formed a clustering analysis of blood gene expression microarray
which classified the 47 pSS patients in three clusters characterized
by IFN and inflammation with no discriminant clinical features
Moreover, four subgroups of patients with similar patients’
clinical characteristics were identified based on absolute cell
counts per μL of blood23. Lastly, a stratification based on patient
clinical phenotypes characterized a posteriori at the molecular
level was proposed43. These works provide good basis for building
a molecular taxonomy of pSS. Our integrative approach using
multi-omics and patient clinical characteristics allows going fur-
ther in understanding pSS heterogeneity.
We identified transcriptional modules allowing to separate pSS
patients into four distinct clusters, irrespective of their treatment,
reflecting specific patterns of immune dysregulation, with disease
activity and patient reported symptom mean scores similar to
naturalistic cohorts like ASSESS44 and UKPSSR 45.
Patients from C2 displayed a healthy-like profile which none-
theless encompasses bona fide pSS patients reporting a similar
level of objective symptoms of dryness, pain and fatigue, albeit a
lower ESSDAI compared to the 3 other clusters. C2 was also
enriched in patients with glandular manifestations of the disease
assessed by a positive focus score and no anti-SSA antibodies. A
similar cluster was recently described42 with no increase in the
IFN modules and minimal activity of inflammation-related gene
modules. Noteworthy, all molecular profiling data reported here
were obtained from blood samples which could affect inter-
pretation of some of the results. For example, the reduction of
peripheral blood pDCs of pSS patients when compared to HV
already reported28 does not consider that pDC are enriched in the
salivary glands and the possibility that tissue sites may be the
major source of IFNα in these individuals46. Extending in
the future those analyses to the salivary gland will provide a more
complete picture of the pathophysiology of the disease,
especially in C2.
The three other clusters exhibited significant differences with
HV and in particular a prominent IFN gene signature. These
findings add to the growing evidence towards a significant role of
the IFN pathways in the pathogenesis of systemic and organ-
specific disorders including pSS. Whereas Type I IFN were pro-
posed as predominant contributors in the pathogenesis of pSS, a
role of Type II IFN in disease pathogenesis has also been
highlighted6,47. Interestingly, our results show that the IFN sig-
nature in the 3 IFN-driven clusters is different. C1 patients had
the highest Type I and Type II IFN scores, C3 a higher Type I IFN
score than C4, these 2 clusters having similar Type II IFN score.
Thus, C4 IFN score was mainly driven by IFN Type II activation.
Consequently, C1 and C3 were similar to the IFN cluster recently
described by James et al.42 also associated with high blood protein
levels of CXCL10/IP-10.
In line with observed IFN scores, circulating serum levels of
IFNα were positively correlated with Type I IFN signature
(Supplementary Fig. 9 and Fig. 3) especially in C1 and to a lesser
extent in C3. However, levels of IFNα in serum were not corre-
lated with ESSDAI global score, but higher levels of serum IFNα
were associated with hematological and biological domains of
ESSDAI.
While C1 was mainly driven by IFN, an increase in frequency
of B lymphocytes in the blood associated with a significant acti-
vation of canonical pathways related to B cell activation such as B
cell receptor signaling, and B cell development were observed in
C3. Main biological features associated with C3 but also C1 were
hypergammaglobulinemia, anti-nuclear antibodies, the presence
of serum anti-SSA52/anti-SSA60 autoantibodies and higher cFLC
confirming what was already reported in autoantibody-positive
pSS patients21. Finally, SNPs associated with HLA class II genes
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Fig. 8 Development of a composite model to predict the belonging of a patient to one of the 4 clusters. a Confusion matrix of the composite model in
the discovery cohort performed for 227 pSS patients (C1: 79, C2: 60, C3: 66, and C4: 22) is shown. b Discriminant function analysis (DFA) of the predicted
patients from the discovery cohort shows clearly separated clusters. Two different views of the same DFA are shown. c DFA of the predicted patients from
the inception cohort shows clearly separated clusters. Two different views of the same DFA are shown. Thirty-seven pSS patients from the inception cohort
were analyzed and predicted as C1: 16, C2: 6, C3: 7, and C4: 8.
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were mainly reported in patients from C1 and C3 presenting a
positive IFN signature and high levels of autoantibodies as
already shown in SLE16.
Patients from C4 exhibited a more severe clinical phenotype
compared to the others with an inflammatory transcriptomic
signature particularly linked to cytokine signaling from the acute
phase response. C4 was also characterized by a massive lym-
phopenia and high levels of neutrophils. The neutrophil-to-
lymphocyte ratio (NLR) has been previously shown to correlate
with disease activity in systemic autoimmunity48,49 and elevated
NLR are thought to represent a pro-inflammatory state. Indeed,
in a study of 483 adult patients with multiple sclerosis, NLR could
differentiate between relapsing-remitting and primary progressive
multiple sclerosis and predict worsening disability50. Further
studies are required in pSS to evaluate the importance of
this ratio.
Because the main current challenge in clinical trials of new
therapies for pSS is the selection of the appropriate patients, we
propose here a combination of molecular parameters allowing
patient classification by endotypes (Supplementary Fig. 14). We
then developed a composite model derived from machine learn-
ing, based on the use of a limited number of transcripts from
whole blood RNASeq and validated in an independent data set
from a pSS inception study, to allow a reanalysis of the previous
and ongoing clinical trials to depict predictors of treatment
response.
These findings have major implications for the treatment of
pSS patients, providing a rationale for both optimal drug posi-
tioning and combinations of drugs with complementary
mechanisms of action. Specifically, our findings provide a strong
rationale for treating patients with either a C1, C3, or C4 profile
with inhibitors of type I IFN responses alone or in combination as
they support the relevance of B cells as potential therapeutic
targets in C3 patients. Trials with B cell depleting antibodies
(rituximab) have shown promising results primarily in reducing
systemic activity in pSS51.
Areas requiring further investigation have been identified.
First, although our identified cluster gene signatures are strong
enough to overcome the disequilibrium in blood cell counts and
are not associated with disease duration, except for C2, RNA-Seq
analysis is oblivious to sample cell-type composition52. Further
analyses are on-going, using deconvolution approaches. Second,
as hypotheses were derived from a cross-sectional study and a
small inception cohort, findings need to be confirmed in long-
itudinal cohorts to clarify whether patients will stay longitudinally
in their initial cluster whatever the disease activity level and the
treatments received, or whether treatments decrease disease
activity by modifying the extent and scope of gene signaling
dysregulations.
Altogether, our results can improve pSS treatment strategies
allowing a patient centric approach. This paradigm already
implemented in the oncology field will increase the probability of
trial successes and boost the development of new efficient drugs
against pSS.
Methods
Computational tools. Except when indicated, data analyses were carried out using
either an assortment of R system software (http://www.R-project.org, V2.10.1)
packages including those of Bioconductor or original R code. R packages are
indicated when appropriate. For GWAS analysis, we used Plink, an open-source
whole genome association analysis toolset. Machine learning approaches were
carried out using python programs (v3.8.5) based on the following modules: scikit-
learn, numpy and xgboost.
Patient population. The present study was conducted in patients with pSS and HV
included in the European multi-center cross-sectional study of the PRECISESADS
IMI consortium which involved patients from seven systemic autoimmune
diseases. This study was a pre-planned substudy to be specifically conducted in the
pSS population and fulfill the STROBE statements (Supplementary note). Diag-
nosis of pSS was made according to the 2002 American-European Consensus
Group classification criteria, with at least the presence of anti-SSA and/or a positive
focus on a minor salivary gland biopsy. Choice of the patient analysis set is detailed
in Supplementary Fig. 1a. Recruitment was performed between December 2014
and October 2017 involving 19 institutions in 9 countries (Austria, Belgium,
France, Germany, Hungary, Italy, Portugal, Spain and Switzerland). The composite
model was validated using transcriptome of 37 pSS newly diagnosed patients
recruited in the inception study also obtained from the PRECISESADS consortium.
Inception patients were recruited by 10 institutions in Spain, Belgium, France, Italy,
Germany and Switzerland. Eligible patients were diagnosed within less than a year
since pSS diagnosis.
The two studies (cross-sectional and inception) adhered to the standards set by
International Conference on Harmonization and Good Clinical Practice (ICH-
GCP), and to the ethical principles that have their origin in the Declaration of
Helsinki (2013). Each patient signed an informed consent prior to study inclusion.
The Ethical Review Boards of the 19 participating institutions approved the
protocol of the cross-sectional study. Moreover, the protocol of the inception study
was approved by the ethical committees of the 10 participating institutions. These
10 sites were also participating to the cross-sectional study, therefore these ethical
committees reviewed both protocols. The ethical committees involved were:
Comitato Etico Milano, Italy; Comité de Protection des Personnes Ouest VI Brest,
France; Louvain, Comité d’Ethique Hospitalo-Facultaire, Belgium; Comissao de
ética para a Saude—CES do CHP Porto, Portugal; Comité Ética de Investigación
Clínica del Hospital Clínic de Barcelona, Spain; Commissie Medische Ethiek UZ
KU Leuven/Onderzoek, Belgium; Geschaftsstelle Ethikkommission, Cologne,
Germany; Ethikkommission Hannover, Germany; Ethik Kommission.
Borschkegasse, Vienna, Austria; Comité de Ética e la Investigación de Centro de
Granada, Spain; Commission Cantonale d‘éthique de la recherche Hopitaux
universitaires de Genève, Switzerland; Csongrad Megyei Kormanyhivatal, Szeged,
Hungary; Ethikkommission, Berlin, Germany; Andalusian Public Health System
Biobank, Granada, Spain.
The protection of the confidentiality of records that could identify the included
subjects is ensured as defined by the EU Directive 2001/20/EC and the applicable
national and international requirements relating to data protection in each
participating country. The cross-sectional and inception studies are registered in
ClinicalTrials.com with respectively number NCT02890121 and number
NCT02890134.
For each individual, blood samples as well as biological and clinical information
were collected as described in the next Methods sections. For more technical details
on sample and data collection, please refer to the main PRECISESADS paper 5.
After quality control on transcriptomics RNAseq data (described below),
verification of the ARC/EULAR classification criteria (focus score ≥ 1 foci/mm²
and anti-SSA/Ro antibody positivity), and match of the HV to the patients based
on age and gender, our final study cohort comprises 304 patients with pSS and 330
HV. This selection is detailed in Supplementary Fig. 1. Among the 304 pSS, 227
(75%) were used for the discovery step and 77 (25%) were kept for validation
(Table 1).
Available data. High-dimensional omics genotype, transcriptome, DNA methy-
lome and proportions of relevant cell types using flow cytometry custom marker
panels were analyzed from whole blood samples. Low dimensional information was
obtained from serum samples, including selected serology information such as
autoantibodies, cytokines, chemokines and inflammatory mediators. Of note,
except for samples collected for flow cytometry analysis, all samples were shipped
by the clinical sites to a Central Biobank (Granada) for processing, storage, and
onward shipment to the analysis sites, where the various determinations were
performed. Flow cytometry was managed at each center on fresh blood after a
multi-center harmonization of flow cytometers to ensure mirroring of all
instruments53,54, thereby allowing subsequent integration of all the data obtained
across the different sites and instruments. Consequently, all the different omics
samples were processed with the same protocols at the same site (RNA-Seq at
Bayer, cytokines at UNIMI, autoantibodies and integrated analyses of flow cyto-
metry at UBO, methylome at IDIBELL, GWAS at CSIC which guarantees the high
quality of the data generated.
Methods used for RNA sequencing, quality control, data processing, and
expression profiling are detailed below and in Supplementary Fig. 1c.
RNA-Seq. Methods used for RNA sequencing, quality control, data processing, and
expression profiling are detailed below and in Supplementary Fig. 1c. Total RNA
was extracted from whole blood samples collected in Tempus tubes using Tempus
Spin technology (Applied Biosystems). 1857 samples were processed in batches of
384, randomized to four 96-well plates with respect to patient diagnosis, recruit-
ment center and RNA extraction date. The samples were depleted in alpha- and
beta-globin mRNAs using globinCLEAR protocol (Ambion) and 1 μg of total RNA
was used as input. Subsequently, 400 ng of globin-depleted total RNA was used for
library synthesis with TruSeq Stranded mRNA HT kit (Illumina). The libraries
were quantified using qPCR with PerfeCTa NGS kit (Quanta Biosciences), and
equimolar amounts of samples from the same 96-well plate were pooled. Four
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pools were clustered on a high output flow cell (two lanes per pool) using HiSeq SR
Cluster kit v4 and the cBot instrument (Illumina). Subsequently, 50 cycles of single-
read sequencing were performed on a HiSeq2500 instrument using and HiSeq SBS
kit v4 (Illumina). The clustering and sequencing steps were repeated for a total of
three runs in order to generate sufficient number of reads per sample. The raw
sequencing data for each run were preprocessed using bcl2fastq software and the
quality was assessed using FastQC tools. Cutadapt55 was used to remove 3′ end
nucleotides below 20 Phred quality score and extraneous adapters, additionally
reads below 25 nucleotides after trimming were discarded. Reads were then pro-
cessed and aligned to the UCSC Homo sapiens reference genome (Build hg19)
using STAR v2.5.2b56. 2-pass mapping with default alignment parameters were
used. To produce the quantification data, we used RSEM v1.2.3157 resulting in gene
level expression estimates (Transcripts Per Million, TPM and read counts).
For sample filtering, samples were filtered in at least one of the following
situations: (i) the total sum of count is too low (<5000,000), (ii) they were extracted
with another method than Tempus Spin, and (iii) the RIN (RNA Integrated
Number) value of the sample is below 6.5, (iv) samples with RNAseq inferred
gender inconsistent with clinical data, and (v) there was a disagreement between
genotypes inferred from RNA-Seq and those obtained from GWAS genotyping.
For normalizations and batch correction, read counts were normalized by the
variance stabilizing transformation vst function from DESeq2 (v1.30.0) R
package58. To reduce the effect of the RIN, a correction was applied using the
ComBat function from sva (v3.38.0) R package59, after categorization of RIN values
into 7 classes: (7.5, 8], (8.5, 9], (9.5, 10], (8, 8.5], (7, 7.5], (9, 9.5], (6.5, 7].
For Gene filtering, among the 55,771 genes detected in the data, those with 0
count over all the samples or having an expression level below 1 in more than 95%
were filtered. At the end, our final RNA-Seq data comprises 16,876 genes. This
selection is detailed in Supplementary Fig. 1.
Molecular subgroups discovery. Our rational was to produce a robust classifi-
cation scheme and to ensure the greatest possible homogeneity within identified
subgroups. To this aim, subgroup discovery was based on the pre-processed RNA-
seq data of the discovery set (after vst transformation). We implemented a strategy
already applied in breast cancer that iterates unsupervised and supervised steps,
which was, therefore, designated as “semi-supervised” approach8. It is described
hereafter and summarized in Supplementary Fig. 2.
Step 1: Unsupervised gene selection
The coefficient of variation (CVg ¼
σg
μg
, with σg is the standard deviation of the
gene g and μg the mean of the gene g estimated on discovery population) and its
robust version (rCVg ¼
γg
μg
, with γg is the median absolute deviation) were
calculated for each gene. Both were highly concordant. The top 25% most variants
were selected to perform the subsequent clustering analysis.
Step 2: Robust consensus clustering
To determine the number of clusters, a consensus clustering between three
methods was performed: (i) Agglomerative Hierarchical Clustering (hclust function
from stats v4.0.2 R package) with Pearson correlation as a similarity measure and
the Ward’s linkage method, (ii) K-means clustering (kmeans function from stats R
package) with 4 groups and (iii) Gaussian mixture clustering (mclust function from
mclust v5.4.6 R package).
Step 3: Identification of molecular signature
A supervised analysis was performed on the 149 patients with consistent cluster
assignments between the three clustering methods (considered as “core” molecular
profils), in order to identify the most discriminating signature of the 4 clusters. The
first signature of set of 3577 genes was selected from a classical one-way ANOVA
(FDR < 1e-10), and then reduced by Random Forest to 257 top discriminating
genes (randomForest function from randomForest v4.6-14 R package60).
Step 4: Robustness classification
To validate the robustness of our clustering, we re-applied Step 2 on our
discovery set and on the final signature.
Step 5: Classification of discordant patients
Patients assigned to different groups with the 3 clustering methods were
assigned to one of the 4 clusters by applying a distance-to-centroid method based
on Pearson correlation.
Molecular subgroup validation. Validation datasets were independently classified
in the pSS molecular subgroups by applying a classical distance-to-centroid
approach based on correlation. Following the same approach, HV did not con-
stitute a separate cluster but mainly matched with C2 (0.5% in C1, 93% in C2, 4%
in C3, and 2.5% in C4) pSS molecular subgroups by applying a classical distance-
to-centroid approach based on correlation. The final clustering (without HV) is
represented with heatmap using the Heatmap function from ComplexHeatmap
(v2.6.2) R package. Clusters are separately constrained for better visualization. This
method allows to spotlight heterogeneous intra-clusters. The principal component
analysis (PCA) representation will explore the clearly defined clusters and the
matching between C2 and HV.
Half of the pSS patients was treated with either anti-malarial,
immunosuppressant, or steroids at the time of the visit. When compared to the 3
other clusters, we observed higher proportion of treated patients in C4. To
investigate the impact of the treatment on the clustering, we compared treated
patients and untreated patients. For this, we apply a hierarchical clustering on
treated patients and untreated patients and compare the cluster distribution. The
heatmap (Supplementary Fig. 4) of treated vs untreated patients were highly similar
which shows that the final clustering is not driven by treatments.
Enrichment analysis. Enrichment analysis was performed by applying a two-tailed
Fisher-exact test61 against different sources of gene modules or pathways: (i)
3 strongly upregulated IFN-annotated modules from10 (M1.2, M3.4, and M5.12)
determined from peripheral blood transcriptomic data with for each a distinct
activation threshold, (ii) genes preferentially induced by IFNα or IFNγ identified
by10, (iii) canonical pathway from Ingenuity Pathway Analysis (IPA, Release Date:
2020-06-01), (iv) repertoire recently established on an expended range of disease
and pathological states (382 transcriptome modules based on genes co-expression
patterns across 16 diseases and 985 unique transcriptome profiles) by 9.
Differential gene expression analysis. To identify genes differentially expressed
between pSS subgroups and HV, we performed a linear model (lmFit function from
limma v3.46.0 R package62) on vst transformation gene expression dataset.
Resulting p-values were adjusted for multiple hypothesis testing and filtered to
retain DE genes with FDR adjusted p-value ≤ 0.05 and a |Fold-Change (FC) | ≥ 1.5.
Genome-wide association study. Genome-wide association studies (GWAS) were
performed for each pSS subgroups (C1: 101, C2: 77, C3: 88, and C4: 38) versus 330
HV. After DNA extraction, the samples were genotyped using HumanCore-24 v1.0
and Infinium CoreExome-24 v1.2 genome-wide SNP genotyping platform (Illu-
mina Inc., San Diego, CA, USA). Individuals were excluded on the basis of
incorrect gender assignment, high missingness (>10%), non- European ancestry
(<55% using Frappe15 and REAP), and high relatedness (PLINK v1.945, pi_hat
>0.5)63. Genotypes were filtered before imputation due to high missingness (>2%),
Hardy–Weinberg equilibrium (HWE) < 0.001, minor allele frequency (MAF) <1%,
and AT/CG changes with MAF >40%. PLINK v1.945 was used to carry out quality
control (QC) measures, genotype data filtering. The basic association for a cluster
trait locus, based on comparing allele frequency between patients from each cluster
vs HV, was also obtained with this toolset thanks to computational resources from
the Roscoff Bioinformatics platform ABiMS. Genotypes were phased using Eagle
v2.3 and imputed using Minimac3 against the HRC v1.1 Genomes reference panel
from the Michigan Imputation Server platform. Genotypes were filtered after
imputation to have HWE p-value > 0.001, MAF > 1% and imputation info score >
0.7 and resulted in 6,664,685 imputed genotypes. Statistical analysis of association
for each cluster versus HV was performed by logistic regression under the additive
allelic model. The GWAS significant level was fixed at p-value < 5 × 10−8. SNP
annotations and Manhattan plot were obtained using the web-based tool SNP snap
from the Broad Institute64 and qqman (v0.1.8)65 R packages respectively.
Methylation. Whole blood methylation analysis was performed for 226 pSS
patients (C1: 81, C2: 57, C3: 62, and C4: 26) and 175 healthy volunteers (HV).
DNA was extracted using a magnetic-bead nucleic acid isolation protocol (Che-
magic DNA Blood Kit special, CHEMAGEN) automated with chemagic Magnetic
Separation Module I (PerkinElmer) from K2EDTA blood tube (lavender cap, BD
Vacutainer) of 10 ml (extractions were performed on 3ml). 2 μg of DNA were sent
for DNA methylation assay. The samples were analyzed using Infinium Human
Methylation 450 K BeadChip (Illumina, Inc., San Diego, CA, USA) which covers
more than 400,000 CpG sites. DNA samples were bisulfite-converted using the EZ
DNA methylation kit (Zymo Research, Orange, CA, USA). After bisulfite con-
version, the remaining assay steps were performed following the specifications
recommended by the manufacturer. The array was hybridized using a temperature
gradient program, and arrays were imaged using a BeadArray Reader (Illumina
Inc., San Diego, CA, USA). Sample QC and functional normalization were com-
pleted using minfi (v3.3) R package66. Briefly, during QC steps, subjects were
removed based on outliers for methylated vs unmethylated signals, deviation from
mean values at control probes, and high proportion of undetected probes (using
minfi default parameters). DNA methylation probes that overlapped with SNPs
(dbSNPs v147), located in sexual chromosomes or considered cross-reactive were
removed. Additionally, only probes quality controlled and shared between both
arrays were used in the subsequent analysis (368,607 probes). Measure of methy-
lation level (B values) were produced for each CpG probe and ranged from 0 (0%
molecules methylated at a particular sites) to 1 (100% molecules methylated).
To identify differentially methylated positions (DMPs) between HV and each
pSS subgroups (C1 to C4), the champ.DMP function of ChAMP (v2.18.3) R
package67 was implemented doing pairwise comparison between each cluster and
HV. Many Δ-beta thresholds were described in the literature and the most
frequently used for whole blood studies in autoimmune diseases were 0.05 (5%
difference) and 0.1 (10% difference). In order to fix the best threshold for our study,
we tested the values of 0.05, 0.075, 0.1, and 0.15 for the absolute ΔBeta.
Supplementary Data 11 presents the numbers of DMPs and genes obtained with
these different thresholds.
Then, we decided to analyze the data in two steps: the first step with a
significant adjusted p-value (Benjamini Hochberg) at 0.1 and an absolute ΔBeta >
0.075. We assumed that a threshold of 0.05 was too low and it would have been
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very difficult to interpret the signification of these defects in methylation for C4. If
we had applied a ΔBeta threshold of 0.1 in the first intention, we could have missed
DMPs. In the second step in order to identify the most robust and significant
signature of hypo and hyper methylated genes, a significant adjusted p-value
(Benjamini Hochberg) at 0.1 and an absolute ΔBeta > 0.15 were applied.
For network viewing, we tested gene lists onto the STRING 9.1 Network of
Known and Predicted Protein–Protein Interactions (http://string-db.org/)68.
Flow cytometry. Multi-parameter flow cytometry analyses have been performed in
eleven different centers from the PRECISESADS consortium. Therefore, the inte-
gration of all data in common bioinformatical and biostatistical investigations has
required a fine mirroring of all instruments54. The calibration procedure elaborated
to achieve this prerequisite and the antibody panels used have been previously
described53.
The antibody panels, specificities, and clones used are shown in Supplementary
Fig. 15a.
The strategy developed to avoid any redundancy in the different cell subsets and to
increase the accuracy of the phenotypes has been automated by AltraBio (Lyon,
France). The generated automatons have been validated in a preliminary study on 300
patients comparing data from automated gating to data manually gated by the same
operator (coefficient of correlation 0.9996). The gating strategy was as follows: after
exclusion of debris, dead cells and doublets, frequencies and absolute numbers of
CD15hiCD16hi neutrophils, CD15hiCD16+ eosinophils, CD14+CD15hi LDGs,
CD14++CD16− classical monocytes, CD14++CD16+ intermediate monocytes,
CD14+CD16++ non classical monocytes, CD3+ T cells (with CD4+CD8-,
CD4+CD8+, CD4−CD8+, CD4−CD8− T cell subsets), CD19+B cells, CD3−CD56+
NK cells (with CD16loCD56hi and CD16hiCD56lo NK cell subsets), CD3+CD56+
NK-like cells, Lin-HLA-DR+ DCs (with CD11c−CD123+ pDCs, CD11c+CD123−
mDCs (with CD141−CD1c+ mDC1, CD141+CD11c− mDC2 and CD141−CD1c−
mDC subsets)) and CD123+HLA-DR− basophils were automatically extracted from
FCS and LMD files of 283 patients and 309 HV and sent in an Excel flow cytometry
workflow. The mean distribution of blood cell subsets in frequency (0–100%) and
absolute numbers by clusters are compared using a Kruskal–Wallis test.
Gating strategies of the automatons are shown in Supplementary Fig. 15b. For
all instruments, the data from the flow cytometry files are analyzed with a similar
strategy by one automaton for panel 1 and another automaton for panel 2, and
then specifically for each instrument from the gate [S4] to account for the
variability of FSC and SSC signals. The desired cell populations are identified by
gating strategies identical for all instruments for panel 1 and panel 2 stainings. The
mean distribution of blood cell subsets in frequency and absolute numbers are
shown in Supplementary Data 12 and 13, respectively.
Cytokines. Cytokines were measured on serum samples. CXCL13/BLC, FAS
Ligand, GDF15, CXCL10/IP-10, CCL8/MCP-2, CCL13/MCP-4, CCL4/MIP-1β,
MMP-8, CCL17/TARC, IL-1 RII, TNF RI, and IL1-Ra were measured using the
Luminex system. The 12-analyte customized panel was built using human pre-
mixed multi-analyte Luminex assay (R&D Systems). Samples were thawed on the
day of analysis and tested in batches. Soluble MMP-2, CRP, TNFα, IL-6, BAFF, and
TGFβ were measured using ELISA assay. Descriptive statistics are shown in Sup-
plementary Data 14. We measured levels of IFNα in plasma using Simoa Single
Molecule Array Technology. Results were calculated referring to a standard curve
created using a four parameters logistic curve fit and were expressed as pg/ml. For
more technical details on sample and data collection, please refer to the main
PRECISESADS study5. The differential cytokine concentration between subgroups
vs HV was performed using a one-way ANOVA followed by post-hoc Tukey’s test
(function ghlt from multicomp multcomp v1.4-13 R package69). The z-score
indicate the direction of the concentration between the cluster and the HV. A
z-score > 0 means that the cluster has an overexpression compare to HV. A
z-score < 0 means that the cluster has a lower expression compare to HV (Fig. 6).
Concentration distribution by subgroup is represented in Supplementary Fig. 8.
Two-tailed pairwise Wilcoxon-rank sum tests have been computed.
Autoantibodies. Autoantibodies (Extractable nuclear antigen antibodies, anti-SSA
antibodies, anti-SSA antibodies (Ro-52), anti-SSA antibodies (Ro-60), Anti-SSB
antibodies), were measured in serum using an automated chemiluminescent
immunoanalyzer (IDS-iSYS). After processing, the final result is indicative of the
concentration of the specific autoantibody present in the sample. Rheumatoid
factor (RF), complement C3c, C4, and individualized (kappa, lambda) free light
chains (Combilite and freelight, respectively) were measured in serum using a
turbidimetric immunoassay method according to manufacturer’s recommenda-
tions (SPAPLUS analyser). For more technical details on sample and data collec-
tion, please refer to the main PRECISESADS study5. Autoantibodies and RF
distribution have been described by concentration level (Negative/Low/Medium/
Elevated/High) and a Fisher’s exact test was applied to compare the proportion and
the concentration across the 4 clusters. Complements C3 and C4 and circulating
free light chains have been described in continued concentration expressed in g/L
and mg/L respectively and a Krukal–Wallis test was applied to compare the con-
centration level across the 4 clusters. Descriptive statistics are described in Sup-
plementary Data 8.
Clinical data. Clinical data on 304 patients with pSS and 330HV describing the
disease phenotype was collected using an electronic case report form (eCRF). A
working group of experts on systemic autoimmune diseases was established and the
desired items were selected via a Delphi technique. A final set of items was created,
digitalized and pilot tested divided into 8 domains (constitutional symptoms, gas-
trointestinal, vascular, heart and lung, nervous system, skin and glands, muscu-
loskeletal, therapy). After the confirmation of patient inclusion, clinical data were
collected including patient’s age, sex, ethnicity, dates of first disease manifestation
(disease onset), clinical and biological characteristics at baseline, the physician global
assessment of disease activity, comorbidity, and current use of treatments.
Another working group of pSS pathology experts was established to select pSS
disease-specific items, mainly pSS disease activity scales like ESSDAI and its
components, and ESSPRI and its components. These items were collected on a pSS
sub-population (n= 193).
To characterize pSS subgroups, association test was performed with clinical
data. A two-tailed Fisher’s exact test (fisher.test function from stats R package) or
chi-square test (chisq.test function from stats R package) as appropriate was
applied to evaluate the association between the pSS supbgroups and a qualitative
clinical factor. A Kruskal–Wallis test (Kruskal.Wallis function from stats R
package) was used to evaluate the association between pSS subgroups and
quantitative clinical variables.
Development of the composite model for cluster prediction. This feature
selection process is composed of two distinct parts: (i) identify a subset of genes
potentially interesting to predict the 4 clusters, (ii) use these previously identified
subsets to actually craft a prediction model and extract the features used by the
model to increase its precision. In the first part, with FC ≥1.5 and FDR ≤0.05, we
selected the DEGs according to the following 7 combinations: C2 vs C1, C3 vs C1,
C4 vs C1, C4 vs C2, C3 vs C2, C4 vs C2, C4 vs C3. We identified 14,240 and
selected those common to all combinations representing 1154 DEGs.
We used the Boruta algorithm70 on all dataset (discovery and validation sets) to
extract features that significantly contributed to predict the patient’s cluster.
The algorithm started to extend the dataset by adding copies of each feature in
the original dataset. These features were called “shadow features” and consisted in
random permutation of the modality of the original feature, in order to remove any
correlation with the target variable, in our case, the cluster assignment. Once
shadow features were crafted, a random forest classifier was run on the whole
dataset and z-scores were computed for all features (real and “shadow”). Shadow
features were then sorted according to their z-score and the maximum score was
kept in memory as a threshold. The algorithm assigned a hit to each real feature
that had a z-score above this threshold. Finally, Boruta marked the features which
had a z-score significantly lower than the shadow with maximum z-score as
“unimportant” and removed them from the dataset, before removing all shadow
features and returning a clean dataset.
This process allowed us to identify variables in the dataset that were significantly
more contributing to the classification problems than noisy variables and random
artefacts emulated by the original variable modality permutation, ensuring the use of
robust features for the second step of our feature selection strategy.
The relatively small size and heterogeneity of C4 in comparison to the other
clusters can impact the feature selection process, therefore we chose to solve two
classification problems: (i) identify C4 versus all clusters, (ii) discriminate between
C1, C2, and C3.
The operation was performed twice: one to predict C4 cluster versus all other
clusters and one to discriminate between C1, C2, and C3. In both cases, the
algorithm ran over 100 iterations with a max depth of 5 and balanced classes for
initializations of random forests.
The two sets of selected features were respectively composed of 255 genes for
the C4 prediction dataset and 597 genes for the C1, C2, and C3 prediction dataset.
We then used xgboost-tree71 approach, to train a model on the dataset with a
binary logistic objective function to predict C4 vs all (using the 255 genes
previously identified by the Boruta algorithm) and to extract features that have
been used by the algorithm to craft the decision tree of the model.
The model can be summarized by ŷi ¼ ∑Kk¼1f k xi
 
; f k 2 F where ŷi is the
cluster prediction for the patient i, xi the vector describing the patient i (composed
of the selected features), F the set of estimators for the model (4 in our case, one for
each cluster) and K the number of trees by estimator which is 3 for C4 and 4 for
C1, C2, and C3. In this context, f k refers to the tree number k of the estimator f
where f 2 F. K has been manually refined in order to find a compromise between
good predictive performance and a low complexity model.
We performed the same approach with a softmax objective function in a multi-
classification context to predict the C1, C2, and C3 cluster based on the 597
features previously highlighted by Boruta for this specific classification problem.
The final sets of selected features were composed of 10 genes for the C4
prediction model and 31 genes for the multi-classification (C1, C2, or C3) model
(Supplementary Fig. 10). The accuracies of the models, during the training phase
perform on the validation set (Table 1) were 94.81% for the C4 prediction model
and 96.72% for the multi-classification model.
We then created a composite model, using the combinatorial results of the C4
predictor model and the multi-classification model to predict all 4 clusters on the
patients of the discovery set.
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Patients were first evaluated by the C4 predictor model. If C4 was not assigned,
the patients were evaluated by the multi-classification model.
In order to allow our model to process other cohorts of patients we
implemented an interpolation function described by (2). We selected 6 genes with
FC ≤ 1.1 and FDR ≥ 0.05 based on their constant expression across all 4 clusters
and HV. Their expressions were between 4 and 14 vst normalized counts [SPIRE
(4), NUP210L (6), GATAD1 (8), HVCN1 (10), ENO (12), and FLNA (14)]
(Supplementary Fig. 13). This set of genes was denoted G. The interpolated value of
a gene x, IðxÞ was computed as I xð Þ ¼ I að Þ þ I bð Þ  I að Þð Þ ´ xaba with a and b
representing the vst normalized expression value of two genes such as genes
a; b 2 G, a < x < b and b≠ a.
The composite model is integrated into an analysis tool available33 and the
pseudocode description is reported in Supplementary Fig. 16.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data included in our study is available upon request at ELIXIR Luxemburg, except the
GWAS data that cannot be anonymized, with the permanent link: https://doi.org/
10.17881/th9v-xt85 and access procedure is described on the ELIXIR data landing page.
The PRECISESADS Consortium committed to secure patient data access through the
ELIXIR platform. This commitment was formerly given by written to all patients at the
end of the project and to the involved Ethical Committees. The future use of the Project
database was framed according to the scope of the patient information and consent
forms, where the use of patient data is limited to scientific research in autoimmune
diseases. ELIXIR reviews applicants requests and prepares Data Access Committee’s
decisions on access to Data, communicates such decisions to the Data Providers, who
have 10 days to exercise their right to veto; otherwise access is granted to the User.
Code availability
Except when indicated, data analyses were carried out using either an assortment of R
system software (http://www.R-project.org, V4.0.1) packages including those of
Bioconductor or original R code. R packages are indicated when appropriate. For GWAS
analysis, we used Plink, an open-source whole genome association analysis toolset.
Machine learning approaches were carried out using python programs (v3.8.5) based on
the following modules: scikit-learn, numpy, and xgboost. The composite model designed
to predict the patient’s cluster is integrated into an analysis tool available on the
laboratory’s github repository at the following address: https://lbai-infolab.github.io/
SjTree/(33).
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